These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 2878934

  • 1. Heterogeneity of Graves' immunoglobulin G: comparison of thyrotropin receptor antibodies in serum and in culture supernatants of lymphocytes transformed by Epstein-Barr virus infection.
    Yokoyama N, Izumi M, Katamine S, Nagataki S.
    J Clin Endocrinol Metab; 1987 Feb; 64(2):215-8. PubMed ID: 2878934
    [Abstract] [Full Text] [Related]

  • 2. Interactions between TSH binding inhibiting--and adenylate cyclase stimulating--antibodies in Graves' disease.
    Morita S, Izumi M, Nagataki S.
    Acta Endocrinol (Copenh); 1986 Aug; 112(4):517-22. PubMed ID: 2875588
    [Abstract] [Full Text] [Related]

  • 3. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, Ohsawa N.
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [Abstract] [Full Text] [Related]

  • 4. Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their incidence, significance and clinical usefulness.
    Macchia E, Concetti R, Borgoni F, Cetani F, Fenzi GF, Pinchera A.
    Autoimmunity; 1989 Aug; 3(2):103-12. PubMed ID: 2577491
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.
    Kim WB, Chung HK, Park YJ, Park DJ, Lee HK, Cho BY.
    Korean J Intern Med; 2001 Sep; 16(3):187-200. PubMed ID: 11769578
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
    Ochi Y, Kajita Y, Hamazu M, Nagata A.
    Horm Res; 2003 Sep; 59(5):222-8. PubMed ID: 12714785
    [Abstract] [Full Text] [Related]

  • 15. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W, Man N, Li YS, Shan ZY, Teng WP.
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y.
    Clin Exp Pharmacol Physiol; 2004 Feb; 31(5-6):314-9. PubMed ID: 15191404
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
    Bossowski A, Stasiak-Barmuta A, Urban M.
    Horm Res; 2005 Feb; 64(4):189-97. PubMed ID: 16220002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.